drugset / Trial / NCT01922154

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

NCT01922154

Phase 4 Completed 15 enrolled Siriraj Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Timeline

Start
2009-02
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.05 ml Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications